AI Science Tracker

AlphaFold2-Multimer screen of the 53BP1 pathway predicts a RIF1-SHLD3 interface that is confirmed in cells

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital · 12 Jan 2023 · biology

Discovery

AlphaFold2-Multimer screen of the 53BP1 pathway predicts a RIF1-SHLD3 interface that is confirmed in cells

Source check: Needs source check. Not independent scientific confirmation.

Finding: Sifri et al. used AlphaFold2-Multimer to predict all pairwise interactions in the 53BP1-RIF1-shieldin-CST pathway, recovered seven known interfaces and predicted a new one between the RIF1 HEAT-repeat domain and the SHLD3 eIF4E-like domain. Pulldown and cellular assays supported the model and showed the interaction is needed for shieldin recruitment, class switch recombination and PARP inhibitor sensitivity. First public version: bioRxiv 2023-01-12; journal version 2023-06-12. Abstract-level review only.

Technology: AlphaFold2-Multimer

Family AlphaFold: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
AlphaFold2-Multimer predicted pairwise complexes and proposed the novel RIF1-SHLD3 interface that guided the experiments.
Test and result
The predicted interface was tested by in vitro pulldown and cellular assays, per the abstract.
Limitation / still unknown
Full Methods, mutant-design details and independent replication were not assessed; the 2023-01-12 date is the bioRxiv posting (10.1101/2023.01.12.523815), version differences not compared.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://europepmc.org/article/MED/37306046 · https://doi.org/10.1101/2023.01.12.523815

Needs source check · editorial details

The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 17 Nov 2026. Review scope: abstract and bibliographic metadata (Europe PMC) only; Methods not assessed.

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse biology discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.